Forbes – Debate: Do High Drug Prices Drive Innovation, Or Hurt It?
0
“After I wrote about the problems of high cancer drug prices in this space (See: “Could High Drug Prices Be Bad For Innovation“), John LaMattina, the former head of R&D at Pfizer and a regular Forbes contributor, took issue with my arguments. He writes:
Dr. Peter B. Bach is a physician at Memorial Sloan Kettering Cancer Center and the Director of its Center for Health Policy and Outcomes. He is a passionate advocate for patients and often eloquently expresses concerns on the high prices of drugs, particularly new cancer therapies. When he speaks, many people including myself pay close attention. However, his guest post on Forbes.com entitled “Could High Drug Prices Be Bad For Innovation” unfortunately is off-base.”
Read more – Forbes